

# VEQ 360°



**Una risorsa indispensabile per confermare e migliorare la qualità di tutto il tuo laboratorio.**

Catalogo 2027

**LABQUALITY**

**Microbiologia**



# Clinical microbiology

The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in the areas of bacterial serology, bacteriology, mycology, parasitology and virology. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, and PCR tests, solutions for versatile needs are available. Authentic single donor samples are included in multiple schemes.

## Bacterial serology

### Antistreptolysin

Target: Laboratories

| 5840 Antistreptolysin |                                                      |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------|------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples               | 2 human single donor plasma or serum samples, 0.4 mL |     |     |     |     |             |     |     |     |     |     |     |
| Examinations          | Qualitative and quantitative ASO.                    |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                | JAN                                                  | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02               |     |     |     |     | Results/set |     | 3   |     |     |     |     |

### Bordetella pertussis, antibodies

Target: Laboratories

| 5950 Bordetella pertussis, antibodies |                                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                               | 2 plasma or serum samples, 0.3 mL                                                                               |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                          | B. pertussis IgA, IgG & IgM antibodies, Pertussis toxin IgA, IgG & IgM, post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                | JAN                                                                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                         | Not accredited                                                                                                  |     |     |     |     | Results/set |     | 3   |     |     |     |     |

### Borrelia burgdorferi, antibodies

Target: Laboratories

| 5960 Borrelia burgdorferi, antibodies, European origin |                                                                                        |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------------------------|----------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                | 2 human single donor plasma or serum samples, 0.5 mL                                   |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                           | B. burgdorferi IgG, IgM and total antibodies, post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                 | JAN                                                                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                          | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                 |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Brucella antibodies

**Target:** Laboratories

| 5850 Brucella antibodies |                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------|-----------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                  | 2 plasma or serum samples, 0.5 mL                               |     |     |     |     |             |     |     |     |     |     |     |
| Examinations             | Brucella IgG, IgM and total antibodies, clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                   | JAN                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation            | Not accredited                                                  |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Chlamydia pneumoniae, antibodies

**Target:** Laboratories

| 5620 Chlamydia pneumoniae, antibodies |                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------|---------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                               | 2 human single donor plasma or serum samples, 0.4 mL                            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                          | C. pneumoniae IgA, IgG, IgM antibodies, post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                             | Not suitable for complement fixation tests (CFT)                                |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                | JAN                                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Francisella tularensis, antibodies

**Target:** Laboratories

| 5851 Francisella tularensis, antibodies |                                                                               |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------|-------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                 | 3 plasma or serum samples, 0.5 mL                                             |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                            | Francisella tularensis IgG, IgM and total antibodies, clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                  | JAN                                                                           | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                           | Not accredited                                                                |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Helicobacter pylori, antibodies

**Target:** Laboratories and POCT

| 5860 Helicobacter pylori, antibodies |                                                                                                                      |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                              | 2 human single donor plasma or serum samples, 0.4 mL                                                                 |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                         | H. pylori IgA, IgG and total antibodies, quantitative and qualitative tests, post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                               | JAN                                                                                                                  | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                        | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                               |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Mycoplasma pneumoniae, antibodies

**Target:** Laboratories and POCT

| 5980 Mycoplasma pneumoniae, antibodies |                                                                                      |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------|--------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                | 2 human single donor plasma or serum samples, 0.3 mL                                 |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                           | M. pneumoniae IgG, IgM and total antibodies, post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                              | Not suitable for complement fixation tests (CFT)                                     |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                 | JAN                                                                                  | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                          | Not accredited                                                                       |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Syphilis serology

**Target:** Laboratories

| 5880 Syphilis serology |                                                                                     |     |     |     |     |             |     |     |     |     |     |     |
|------------------------|-------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                | 2 human single donor plasma or serum samples, 0.6 mL                                |     |     |     |     |             |     |     |     |     |     |     |
| Examinations           | Cardiolipin, Treponema pallidum antibodies, post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                 | JAN                                                                                 | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation          | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                              |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Bacteriology

### Bacteriological staining, direct

**Target:** Laboratories

| 5050 Bacteriological staining, direct |                                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                               | 3 cases, 3–9 digital images.                                                                          |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                          | Interpretation of digital images taken from direct bacteriological Gram staining of clinical samples. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                | JAN                                                                                                   | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Blood culture

**Target:** Laboratories

| 5100 Blood culture (incl. sepsis multiplex methods) |                                                                                                                                                                                                                                         |     |     |     |     |                    |     |     |     |     |     |     |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                      | 3 lyophilized samples. Brief case histories also given. Fresh blood is needed in the specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and clinical strains. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                 | Culture, identification, antimicrobial susceptibility testing. Direct nucleic acid detection from positive blood culture bottles by multiplex methods is included in the scheme.                                                        |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                    | Fresh blood is needed but not included in the shipment.                                                                                                                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                       | JAN                                                                                                                                                                                                                                     | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                                  |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

| 5101 Blood culture, screening (incl. sepsis multiplex methods) |                                                                                                                                                                                                                                            |     |     |     |     |                    |     |     |     |     |     |     |
|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                 | 3 lyophilized samples. Brief case histories also given. Fresh blood is needed in the specimen preparation.                                                                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                            | Culture, preliminary identification using Gram staining and/or direct nucleic acid detection from positive blood culture bottles by multiplex methods. The scheme is also suitable for stem cell banks screening only for possible growth. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                               | Fresh blood is needed but not included in the shipment.                                                                                                                                                                                    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                                  | JAN                                                                                                                                                                                                                                        | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                           | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                                     |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Bordetella pertussis/parapertussis, nucleic acid detection

**Target:** Laboratories

| 5241 Bordetella pertussis/parapertussis, nucleic acid detection |                                                            |     |     |     |     |                    |     |     |     |     |     |     |
|-----------------------------------------------------------------|------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                  | 2 simulated samples, 1 mL                                  |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                             | Bordetella pertussis/parapertussis, nucleic acid detection |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                                   | JAN                                                        | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                            | Not accredited                                             |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Cerebrospinal fluid, bacterial culture

**Target:** Laboratories

| 5150 Cerebrospinal fluid, bacterial culture |                                                                                                                                                  |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                              | 2 lyophilized samples. Brief case histories also given.                                                                                          |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                         | Culture and identification. The scheme is also suitable for laboratories performing screening and reporting merely a preliminary identification. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                            | See also scheme 5303 Meningitis-encephalitis multiplex, nucleic acid detection                                                                   |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                               | JAN                                                                                                                                              | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                        | Not accredited                                                                                                                                   |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Chemokine CXCL13

**Target:** Laboratories

| 5965 Chemokine CXCL13 |                            |     |     |     |     |                    |     |     |     |     |     |     |
|-----------------------|----------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>        | 2 liquid samples           |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>   | Chemokine CXCL13 detection |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>         | JAN                        | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>  | Not accredited             |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Chlamydia trachomatis and Neisseria gonorrhoeae, nucleic acid detection

**Target:** Laboratories

| 5612 Chlamydia trachomatis and Neisseria gonorrhoeae, nucleic acid detection |                                                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                               | 3 simulated swab/urine samples, 2 mL                                                                            |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                                          | Detection of C. trachomatis and N. gonorrhoeae nucleic acid.                                                    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                                             | See also scheme 5302 Sexually transmitted diseases multiplex, nucleic acid detection. The samples contain hDNA. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                                                | JAN                                                                                                             | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                          |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

Clostridioides difficile

Target: Laboratories

| 5200 Clostridioides difficile, culture and toxin detection |                                                                                                                                                     |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                    | 2 lyophilized mixtures of bacteria                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                               | C. difficile culture, antigen detection (GDH), toxin detection and direct nucleic acid detection. Hypervirulent C. difficile strains also included. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                     | JAN                                                                                                                                                 | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                              | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                              |     |     |     |     | Results/set |     | 1   |     |     |     |     |

| 5201 Clostridioides difficile, nucleic acid detection |                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------|----------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                               | 2 lyophilized mixtures of bacteria                                               |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                          | Direct nucleic acid detection. Hypervirulent C. difficile strains also included. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                             | 5200 includes also this examination.                                             |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                | JAN                                                                              | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                           |     |     |     |     | Results/set |     | 1   |     |     |     |     |

Faecal culture

Target: Laboratories

| 5190 Faecal culture |                                                                                                                                                                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples             | 2 lyophilised mixtures of bacteria.                                                                                                                                                                                                                              |     |     |     |     |             |     |     |     |     |     |     |
| Examinations        | Culture, identification and antimicrobial susceptibility (rounds 2 and 4). In addition to culture, samples are also suitable for direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, Plesiomonas, Salmonella, Shigella and Yersinia. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info           | 5190 includes 5180 Salmonella culture.                                                                                                                                                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
| Rounds              | JAN                                                                                                                                                                                                                                                              | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation       | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                                                           |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## General Bacteriology

**Target:** Laboratories

### 5080 General Bacteriology 1, aerobes and anaerobes

|                      |                                                                                                                                                                                                                                                                                                                          |     |     |     |     |                    |     |     |     |     |     |     |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>       | 4 lyophilized mixtures of microbes: both pathogens and normal flora. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>  | Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical indicators.                                                                                                                                                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>     | 5080 includes 5081, General Bacteriology 2.                                                                                                                                                                                                                                                                              |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>        | JAN                                                                                                                                                                                                                                                                                                                      | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b> | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. Integrated pre- and/or post-analytical cases are not accredited.                                                                                                                                                                                                                 |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

### 5081 General Bacteriology 2, aerobes

|                      |                                                                                                                                                                                                                                                                                                                            |     |     |     |     |                    |     |     |     |     |     |     |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>       | 2 lyophilized mixtures of microbes: both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>  | Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical indicators.                                                                                                                                                                                                                   |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>     | 5080 General Bacteriology 1 includes 5081.                                                                                                                                                                                                                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>        | JAN                                                                                                                                                                                                                                                                                                                        | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b> | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. Integrated pre- and/or post-analytical cases are not accredited.                                                                                                                                                                                                                   |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Gram stain, blood culture

**Target:** Laboratories

### 5041 Gram stain, blood culture

|                      |                                                                                      |     |     |     |     |                    |     |     |     |     |     |     |
|----------------------|--------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>       | 2 air-dried, unfixed microbe suspensions on slides. Brief case histories also given. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>  | Staining and microscopy.                                                             |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>        | JAN                                                                                  | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b> | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                               |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

Gram stain, colonies

Target: Laboratories

| 5040 Gram stain, colonies |                                                      |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------|------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                   | 3 air-dried, unfixed microbe suspensions on a slide. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations              | Staining and microscopy.                             |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                    | JAN                                                  | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation             | SFS-EN ISO/IEC 17043:2023, FINAS, PT02               |     |     |     |     | Results/set |     | 1   |     |     |     |     |

Gram stain, vaginal fluid

Target: Laboratories

| 5043 Gram stain, vaginal fluid |                                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------|-------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                        | Digital or virtual microscopy images of three Gram-stained vaginal fluid samples with brief case histories. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                   | Evaluation of Gram-stained vaginal fluid                                                                    |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                         | JAN                                                                                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                  | Not accredited                                                                                              |     |     |     |     | Results/set |     | 3   |     |     |     |     |

Helicobacter pylori, antigen detection in faeces

Target: Laboratories and POCT

| 5596 Helicobacter pylori, antigen detection in faeces |                                        |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------|----------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                               | 3 lyophilised faecal samples           |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                          | H. pylori antigen detection            |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                | JAN                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | Results/set |     | 3   |     |     |     |     |

Helicobacter pylori, drug resistance, nucleic acid detection

Target: Laboratories

| 5253 Helicobacter pylori, drug resistance, nucleic acid detection |                                                                  |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------------------|------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                           | 3 simulated swab samples.                                        |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                      | H. pylori nucleic acid detection, clarithromycin susceptibility. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                            | JAN                                                              | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                     | Not accredited                                                   |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Legionella, antigen detection in urine

**Target:** Laboratories and POCT

| 5597 Legionella, antigen detection in urine |                                        |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------------|----------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                              | 3 simulated urine samples.             |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                         | Legionella antigen detection.          |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                               | JAN                                    | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                        | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Mycobacteria

**Target:** Laboratories

| 5220 Mycobacterial culture and stain |                                                                                                                                               |     |     |     |     |                    |     |     |     |     |     |     |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                       | 2 lyophilised samples and 2 fixed smears on slides.                                                                                           |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                  | Detection of Mycobacterium tuberculosis and atypical mycobacteria: culture, direct nucleic acid detection, acid-fast staining and microscopy. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                     | See also product 5250 IGRA for M. tuberculosis.                                                                                               |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                        | JAN                                                                                                                                           | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                 | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                        |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

| 5221 Mycobacterial nucleic acid detection |                                                                                        |     |     |     |     |                    |     |     |     |     |     |     |
|-------------------------------------------|----------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                            | 2 lyophilised samples and 2 fixed smears on slides.                                    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                       | Direct nucleic acid detection                                                          |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                          | 5220 includes also this examination. For additional set of samples, order scheme 5222. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                             | JAN                                                                                    | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                      | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                 |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

| 5222 Mycobacteria, extra set of samples |                                              |     |     |     |     |     |     |     |     |     |     |     |
|-----------------------------------------|----------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                          | 2 lyophilised samples.                       |     |     |     |     |     |     |     |     |     |     |     |
| <b>Add. info</b>                        | Only in connection with scheme 5220 or 5221. |     |     |     |     |     |     |     |     |     |     |     |
| <b>Rounds</b>                           | JAN                                          | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |

| 5240 Mycobacterial stain |                                        |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------|----------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                  | 2 fixed smears on slides.              |     |     |     |     |             |     |     |     |     |     |     |
| Examinations             | Acid-fast staining and microscopy.     |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                   | JAN                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation            | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | Results/set | 1   |     |     |     |     |     |

### Mycobacterium tuberculosis, drug resistance, nucleic acid detection

Target: Laboratories

| 5230 Mycobacterium tuberculosis, drug resistance, nucleic acid detection |                                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                                  | 2 simulated samples, 1 mL                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                             | Mycobacterium tuberculosis nucleic acid detection, rifampicin susceptibility and isoniazid susceptibility |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                                   | JAN                                                                                                       | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                            | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                    |     |     |     |     | Results/set | 3   |     |     |     |     |     |

| 5231 Mycobacterium tuberculosis, drug resistance, nucleic acid detection, extra set of samples |                                     |     |     |     |     |     |     |     |     |     |     |     |
|------------------------------------------------------------------------------------------------|-------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Samples                                                                                        | 2 simulated samples, 1 mL           |     |     |     |     |     |     |     |     |     |     |     |
| Add. info                                                                                      | Only in connection with scheme 5230 |     |     |     |     |     |     |     |     |     |     |     |
| Rounds                                                                                         | JAN                                 | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |

### Mycoplasma genitalium, drug resistance, nucleic acid detection

Target: Laboratories

| 5254 Mycoplasma genitalium, drug resistance, nucleic acid detection |                                                                                                                                                            |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                             | 3 simulated swab samples.                                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                        | M. genitalium nucleic acid detection, macrolide (azithromycin) susceptibility. Some rounds will include a fluoroquinolone (moxifloxacin) resistant sample. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                           | The samples contain hDNA.                                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                              | JAN                                                                                                                                                        | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                       | Not accredited                                                                                                                                             |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Neisseria gonorrhoeae (Gc), culture and susceptibility testing

**Target:** Laboratories

| 5120 Neisseria gonorrhoeae (Gc), culture and susceptibility testing |                                                                                                                                                                                           |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                      | 2 lyophilized mixtures of microbes. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                                 | Culture, identification and antimicrobial susceptibility testing. Also suitable for laboratories performing preliminary screening.                                                        |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                                       | JAN                                                                                                                                                                                       | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                                | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                    |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Salmonella culture

**Target:** Laboratories

| 5180 Salmonella culture |                                        |     |     |     |     |                    |     |     |     |     |     |     |
|-------------------------|----------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>          | 2 lyophilised mixtures of bacteria.    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>     | Culture                                |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>        | 5190 also includes 5180.               |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>           | JAN                                    | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>    | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Streptococcus agalactiae (GBS), culture

**Target:** Laboratories

| 5594 Streptococcus agalactiae (GBS), culture |                                                                       |     |     |     |     |                    |     |     |     |     |     |     |
|----------------------------------------------|-----------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                               | 2 lyophilized samples. Samples include pathogens and/or normal flora. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                          | Culture                                                               |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                             | See also product 5599 for direct nucleic acid detection.              |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                | JAN                                                                   | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                         | Not accredited                                                        |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Streptococcus agalactiae (GBS), nucleic acid detection

**Target:** Laboratories, hospital wards

| 5599 Streptococcus agalactiae (GBS), nucleic acid detection |                                                       |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------------|-------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                     | 2 swab samples. Samples also include normal flora     |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                | Direct nucleic acid detection                         |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                   | See also product 5594 for S. agalactiae (GBS) culture |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                      | JAN                                                   | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                               | Not accredited                                        |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Streptococcus pneumoniae, antigen detection

**Target:** Laboratories and POCT

| 5598 Streptococcus pneumoniae, antigen detection in urine |                                        |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------------------------|----------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                   | 3 simulated urine samples.             |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                              | S. pneumoniae antigen detection.       |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                    | JAN                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                             | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Streptococcus pyogenes (Group A), detection in pharyngeal sample

**Target:** Laboratories and POCT

| 5592 Streptococcus pyogenes (Group A), detection in pharyngeal sample, extra set of samples |                                      |     |     |     |     |     |     |     |     |     |     |     |
|---------------------------------------------------------------------------------------------|--------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Samples                                                                                     | 3 simulated samples                  |     |     |     |     |     |     |     |     |     |     |     |
| Add. info                                                                                   | Only in connection with scheme 5595. |     |     |     |     |     |     |     |     |     |     |     |
| Rounds                                                                                      | JAN                                  | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |

| 5595 Streptococcus pyogenes (Group A), detection in pharyngeal sample |                                        |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------------------------------------|----------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                               | 3 simulated samples                    |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                          | Strep A Ag, Strep A NAT                |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                                | JAN                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | Results/set | 3   |     |     |     |     |     |

Surveillance for multidrug resistant bacteria

Target: Laboratories

| 5071 Surveillance for multidrug resistant bacteria, MRSA |                                                                                                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                  | 1 lyophilized mixture of microbes; including pathogens and/or normal flora.                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                             | The product is intended for laboratories performing screening of MRSA (methicillin resistant Staphylococcus aureus) by culture and/or direct nucleic acid detection method. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                | Product 5071 is delivered simultaneously with products 5072 and 5073.                                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                   | JAN                                                                                                                                                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                            | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                      |     |     |     |     | Results/set | 1   |     |     |     |     |     |

| 5072 Surveillance for multidrug resistant bacteria, VRE |                                                                                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                 | 1 lyophilized mixture of microbes; including pathogens and/or normal flora.                                                                                     |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                            | The product is intended for laboratories performing screening of VRE (vancomycin-resistant enterococci) by culture and/or direct nucleic acid detection method. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                               | Product 5072 is delivered simultaneously with products 5071 and 5073.                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                  | JAN                                                                                                                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                           | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                          |     |     |     |     | Results/set | 1   |     |     |     |     |     |

| 5073 Surveillance for multidrug resistant bacteria, gramnegative rods |                                                                                                                                                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                               | 1 lyophilized mixture of microbes; including pathogens and/or normal flora.                                                                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                          | The product is intended for laboratories performing screening of multidrug resistant gramnegative rods (e.g. CPE, ESBL, pAmpC, MDR Acinetobacter and P. aeruginosa) by culture and/or direct nucleic acid detection method. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                             | Product 5073 is delivered simultaneously with products 5071 and 5072.                                                                                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                                | JAN                                                                                                                                                                                                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                      |     |     |     |     | Results/set | 1   |     |     |     |     |     |

## Throat streptococcal culture

**Target:** Laboratories

| 5140 Throat streptococcal culture |                                                              |     |     |     |     |                    |     |     |     |     |     |     |
|-----------------------------------|--------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                    | 3 lyophilised mixtures of bacteria.                          |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>               | Culture and identification of group A, C and G streptococci. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                     | JAN                                                          | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>              | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                       |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Urine culture

**Target:** Laboratories

| 5060 Urine culture, quantitative screening |                                                                                                                              |     |     |     |     |                    |     |     |     |     |     |     |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                             | 2 lyophilized samples and dilutor. Brief case histories also given. Pre- and/or post-analytical cases in part of the rounds. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                        | Culture and quantitation, pre-and/or post-analytical indicators                                                              |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                           | Note also product 3170 Urine bacterial screening with automated analyzers                                                    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                              | JAN                                                                                                                          | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                       | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. Integrated pre- and/or post-analytical cases are not accredited.                     |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

| 5065 Urine culture, quantitative screening, identification and susceptibility |                                                                                                                                                                                                                                                                                    |     |     |     |     |                    |     |     |     |     |     |     |
|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                                | 2 lyophilized samples and dilutor. Brief case histories also given. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Pre- and/or post-analytical cases in part of the rounds. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                                           | Culture, quantitation, identification and antimicrobial susceptibility testing, pre-and/or post-analytical indicators                                                                                                                                                              |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                                              | Note also product 3170 Urine bacterial screening with automated analyzers                                                                                                                                                                                                          |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                                                 | JAN                                                                                                                                                                                                                                                                                | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                                          | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. Integrated pre- and/or post-analytical cases are not accredited.                                                                                                                                                                           |     |     |     |     | <b>Results/set</b> |     | 1   |     |     |     |     |

## Multiplex methods

Multiplex EQA schemes are aimed to support laboratories to fulfill quality requirements of multiplex nucleic acid tests. All schemes include clinically relevant samples specially designed for multiplex nucleic acid testing. The multiplex schemes are annual programs and during the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

### Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

**Target:** Laboratories

| 5305 Bacterial vaginosis and vaginitis multiplex, nucleic acid detection |                                                                                                                                                                                                                                                                                                     |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                                  | 3 simulated swab samples.                                                                                                                                                                                                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                             | Atopobium vaginae, BVAB2, Gardnerella vaginalis, Lactobacillus spp., Megasphaera-1, Candida albicans, Candida glabrata, Candida krusei and Trichomonas vaginalis. Interpretation of bacterial vaginosis.                                                                                            |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                                | During the period of one calendar year, a comprehensive selection of listed microbes will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage. The samples contain hDNA. Product is not suitable for Hologic Aptima BV assay. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                                   | JAN                                                                                                                                                                                                                                                                                                 | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                            | Not accredited                                                                                                                                                                                                                                                                                      |     |     |     |     | Results/set |     | 1   |     |     |     |     |

### Faecal bacterial pathogens multiplex, nucleic acid detection

**Target:** Laboratories

| 5191 Faecal bacterial pathogens multiplex, nucleic acid detection |                                                                                                                                                                                                                                         |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                           | 3 samples. Either lyophilised mixtures of bacteria and/or simulated samples, 1 mL.                                                                                                                                                      |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                      | Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, C. difficile, E. coli EHEC (stx1/stx2), E. coli EAEC, E. coli EIEC, E. coli EPEC, E. coli ETEC, Plesiomonas, Salmonella, Shigella, Vibrio and Yersinia. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                         | During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage.                   |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                            | JAN                                                                                                                                                                                                                                     | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                     | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                                  |     |     |     |     | Results/set | 1   |     |     |     |     |     |

## Faecal parasites multiplex, nucleic acid detection

Target: Laboratories

| 5472 Faecal parasites multiplex, nucleic acid detection |                                                                                                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                 | 3 samples. Either lyophilised and/or simulated samples, 1 mL.                                                                                                               |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                            | Nucleic acid detection of <i>Cryptosporidium</i> , <i>Cyclospora cayetanensis</i> , <i>Dientamoeba fragilis</i> , <i>Entamoeba histolytica</i> and <i>Giardia lamblia</i> . |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                  | JAN                                                                                                                                                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                           | Not accredited                                                                                                                                                              |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Gastrointestinal viral multiplex, nucleic acid detection

Target: Laboratories

| 5304 Gastrointestinal viral multiplex, nucleic acid detection |                                                                                                                                                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                       | 3 simulated samples, 1 mL.                                                                                                                                                                                            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                  | Direct multiplex nucleic acid detection. Pathogens included are: Adenovirus, Astrovirus, Norovirus GI and GII, Rotavirus and Sapovirus.                                                                               |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                     | During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                        | JAN                                                                                                                                                                                                                   | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                 | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Joint infection multiplex, nucleic acid detection

Target: Laboratories

| 5558 Joint infection multiplex, nucleic acid detection |                                                                                                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                | 3 simulated samples.                                                                                                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                           | Direct nucleic acid detection of pathogens included in joint infection multiplex panels.                                                                                                         |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                              | During the period of one calendar year, a selection of pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                 | JAN                                                                                                                                                                                              | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                          | Not accredited                                                                                                                                                                                   |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Meningitis-encephalitis multiplex, nucleic acid detection

Target: Laboratories

| 5303 Meningitis-encephalitis multiplex, nucleic acid detection |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                        | 3 simulated samples, 1 mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                   | Direct multiplex nucleic acid detection. Pathogens included are: Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, Cytomegalovirus (CMV), Enterovirus, Epstein-Barr virus (EBV), Herpes simplex virus 1 (HSV1), Herpes simplex virus 2 (HSV2), Human herpesvirus 6 (HHV6), Human parechovirus (HPeV), Varicella zoster virus (VZV), Cryptococcus neoformans and Cryptococcus neoformans/gattii. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                      | During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage.                                                                                                                                                                                                                                                                          |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                         | JAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                  | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. The qualitative analysis phase is accredited.                                                                                                                                                                                                                                                                                                                                                                                                          |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Respiratory infections multiplex, nucleic acid detection

Target: Laboratories

| 5300 Respiratory infections multiplex, nucleic acid detection |                                                                                                                                                                                                                                                                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                       | 4 simulated samples, 1 mL each                                                                                                                                                                                                                                                                                                            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                  | Direct multiplex nucleic acid detection. Pathogens included are adenovirus, bocavirus, B. parapertussis, B. pertussis, C. pneumoniae, coronavirus (OC43, 229E, NL63, HKU1), enterovirus, influenza virus A/B, L. pneumophila, metapneumovirus, M. pneumoniae, parainfluenza virus 1-4, rhinovirus, RSV A/B, SARS-CoV-2 and S. pneumoniae. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                     | During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage. The samples include hDNA.                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                        | JAN                                                                                                                                                                                                                                                                                                                                       | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                 | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. The qualitative analysis phase is accredited.                                                                                                                                                                                                                                                     |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Sexually transmitted diseases multiplex, nucleic acid detection

Target: Laboratories

| 5302 Sexually transmitted diseases multiplex, nucleic acid detection |                                                                                                                                                                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                              | 4 simulated swab/urine samples, 2 mL.                                                                                                                                                                                                           |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                         | Direct multiplex nucleic acid detection. Pathogens included are C. trachomatis, M. genitalium, M. hominis, N. gonorrhoeae, T. vaginalis, U. parvum and U. urealyticum.                                                                          |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                            | During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage. The samples contain hDNA. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                               | JAN                                                                                                                                                                                                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                        | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                                                                                          |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Tropical fever multiplex, nucleic acid detection

Target: Laboratories

| 5557 Tropical fever multiplex, nucleic acid detection |                                                                                                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                               | 3 simulated samples.                                                                                                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                          | Direct nucleic acid detection of pathogens included in tropical fever multiplex panels.                                                                                                          |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                             | During the period of one calendar year, a selection of pathogens will be covered. Participation in all rounds throughout the year is strongly recommended to achieve the best possible coverage. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                | JAN                                                                                                                                                                                              | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                         | Not accredited                                                                                                                                                                                   |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Mycology

### Candidozyma auris (ex Candida auris), nucleic acid detection

Target: Laboratories and POCT

| 5262 Candidozyma auris (ex Candida auris), nucleic acid detection |                                           |     |     |     |     |             |     |     |     |     |     |     |
|-------------------------------------------------------------------|-------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                           | 2 simulated swab samples                  |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                                      | Candidozyma auris (ex Candida auris) NAT. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                            | JAN                                       | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                                     | Not accredited                            |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Fungal culture

Target: Laboratories

| 5260 Fungal culture |                                                                                                                   |     |     |     |     |             |     |     |     |     |     |     |
|---------------------|-------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples             | 3 lyophilised samples. Brief case histories also given. The samples may include moulds, dermatophytes and yeasts. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations        | Culture and identification. Antimicrobial susceptibility testing of yeast strains.                                |     |     |     |     |             |     |     |     |     |     |     |
| Rounds              | JAN                                                                                                               | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation       | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                            |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Fungal infections, nucleic acid detection

Target: Laboratories

| 5261 Fungal infections, nucleic acid detection |                                                                                                                     |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                        | 3-4 simulated samples. The samples may include yeasts, dermatophytes and moulds.                                    |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                   | Nucleic acid detection according to laboratory's own test selection.                                                |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                      | Test selection of the participating lab is taken into consideration in result processing. The samples contain hDNA. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                         | JAN                                                                                                                 | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                  | Not accredited                                                                                                      |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Parasitology

### Cryptosporidium/Giardia/Entamoeba, antigen detection

Target: Laboratories and POCT

| 5476 Cryptosporidium/Giardia/Entamoeba, antigen detection |                                                                                        |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------------------------|----------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                   | 3 simulated swab samples                                                               |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                              | Antigen detection: Cryptosporidium parvum, Giardia lamblia, and Entamoeba histolytica. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                    | JAN                                                                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                             | Not accredited                                                                         |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Macroscopic findings in parasitology

**Target:** Laboratoriot

| 5477 Macroscopic findings in parasitology |                                                                                                                                                                                                                                                                         |     |     |     |     |                    |     |     |     |     |     |     |
|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                            | 4 cases, 4-8 digital images. Brief case histories also given.                                                                                                                                                                                                           |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                       | Helminth identification, insect larva identification, ectoparasite identification. Interpretation of digital images.                                                                                                                                                    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                          | Ectoparasites and endoparasites (such as arthropods, larvae, helminths, or their fragments), or structures or organisms suspected of being parasitic. The material may also include microscope images of small multicellular organisms or detailed parasite structures. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                             | JAN                                                                                                                                                                                                                                                                     | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                      | Not accredited                                                                                                                                                                                                                                                          |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Malaria, antigen and nucleic acid detection

**Target:** Laboratories and POCT

| 5430 Malaria, antigen and nucleic acid detection |                                                                                                                                                               |     |     |     |     |                    |     |     |     |     |     |     |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                   | 3 whole blood samples. The scheme contains primarily Plasmodium falciparum positive and negative samples, occasionally other Plasmodium species are included. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                              | Antigen and nucleic acid detection. Target antigens: HRP2 and/or pLDH and/or aldolase.                                                                        |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                    | JAN                                                                                                                                                           | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                             | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                        |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

| 5431 Malaria, antigen and nucleic acid detection, extra set of samples |                                     |     |     |     |     |     |     |     |     |     |     |     |
|------------------------------------------------------------------------|-------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                         | 3 whole blood samples               |     |     |     |     |     |     |     |     |     |     |     |
| <b>Add. info</b>                                                       | Only in connection with scheme 5430 |     |     |     |     |     |     |     |     |     |     |     |
| <b>Rounds</b>                                                          | JAN                                 | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |

## Parasites in blood

**Target:** Laboratories

| 5460 Parasites in blood, Giemsa stain |                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------|---------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                        | 2 methanol fixed or Giemsa stained smears. Brief case histories are also given. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                   | Screening and identification of malaria plasmodia and other blood parasites.    |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                         | JAN                                                                             | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                  | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                          |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

#### 5461 Parasites in blood, MGG stain

|               |                                                                                              |     |     |     |     |             |     |     |     |     |     |     |
|---------------|----------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples       | 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations  | Screening and identification of malaria plasmodia and other blood parasites.                 |     |     |     |     |             |     |     |     |     |     |     |
| Rounds        | JAN                                                                                          | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                       |     |     |     |     | Results/set |     | 3   |     |     |     |     |

#### 5462 Malaria screening, Giemsa stain

|               |                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|---------------|---------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples       | 2 methanol fixed or Giemsa stained smears. Brief case histories are also given. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations  | Preliminary screening of malaria plasmodia                                      |     |     |     |     |             |     |     |     |     |     |     |
| Rounds        | JAN                                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

#### 5463 Malaria screening, MGG stain

|               |                                                                                              |     |     |     |     |             |     |     |     |     |     |     |
|---------------|----------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples       | 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations  | Preliminary screening of malaria plasmodia                                                   |     |     |     |     |             |     |     |     |     |     |     |
| Rounds        | JAN                                                                                          | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                       |     |     |     |     | Results/set |     | 3   |     |     |     |     |

### Parasites in faeces

Target: Laboratories

#### 5440 Parasites in faeces

|               |                                                                           |     |     |     |     |             |     |     |     |     |     |     |
|---------------|---------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples       | 3 stool samples in formalin. Brief case histories also given.             |     |     |     |     |             |     |     |     |     |     |     |
| Examinations  | Screening and identification of intestinal parasites (ova and parasites). |     |     |     |     |             |     |     |     |     |     |     |
| Rounds        | JAN                                                                       | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                    |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Parasites in faeces, virtual microscopy

**Target:** Laboratories

| 5450 Parasites in faeces, virtual microscopy |                                                                                                                                  |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                      | Virtual whole slide images of stool samples in formalin prepared by using a scanner microscope. Brief case histories also given. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                 | Screening and identification of intestinal parasites (ova and parasites).                                                        |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                       | JAN                                                                                                                              | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                | Not accredited                                                                                                                   |     |     |     |     | Results/set |     | 5   |     |     |     |     |

## Toxoplasma antibodies

**Target:** Laboratories

| 5420 Toxoplasma, antibodies |                                                                                                |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------|------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                     | 3 human single donor plasma or serum samples, 0.7 mL. Brief case histories also given.         |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                | Toxoplasma IgG, IgM and total antibodies, IgG avidity, post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                      | JAN                                                                                            | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation               | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                         |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Trichomonas vaginalis, detection

**Target:** Laboratories and POCT

| 5473 Trichomonas vaginalis, detection |                                                                   |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------|-------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                               | 2 simulated samples                                               |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                          | Detection of Trichomonas vaginalis antigen and nucleic acid (NAT) |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                             | The samples contain hDNA.                                         |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                | JAN                                                               | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                            |     |     |     |     | Results/set |     | 3   |     |     |     |     |

# Virology

## CMV and EBV, nucleic acid detection, quantitative

Target: Laboratories

| 5651 CMV and EBV, nucleic acid detection, quantitative |                                |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------------------------|--------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                | 5 simulated samples            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                           | CMV and EBV NAT                |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                              | Quantitative result processing |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                 | JAN                            | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                          | Not accredited                 |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Cytomegalovirus, antibodies

Target: Laboratories

| 5650 Cytomegalovirus, antibodies |                                                                                                         |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------|---------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                          | 3 human single donor plasma or serum samples, 0.7 mL                                                    |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                     | Cytomegalovirus IgG, IgM and total antibodies, IgG avidity and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                           | JAN                                                                                                     | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                    | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                  |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Dengue virus, antibodies and antigen detection

Target: Laboratories and POCT

| 5635 Dengue virus, antibodies and antigen detection |                                                                                                              |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                             | 3 human single donor plasma or serum samples, 0.5 mL. Occasionally simulated samples                         |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                        | Dengue virus IgG and IgM antibodies, Dengue virus antigen (NS1) and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                              | JAN                                                                                                          | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                       | Not accredited                                                                                               |     |     |     |     | Results/set |     | 3   |     |     |     |     |

EBV mononucleosis

Target: Laboratories

| 5641 EBV mononucleosis, specific antibodies |                                                                                             |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------|---------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                     | 3 human single donor plasma or serum samples, 1.4 mL                                        |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                | EBNA AbG, EBV VCA AbG, EBV VCA AbM, IgG Avidity and post-analytical clinical interpretation |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                      | JAN                                                                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                               | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                      |     |     |     |     | Results/set |     | 3   |     |     |     |     |

EBV mononucleosis, POCT

Target: Laboratories and POCT

| 5640 EBV mononucleosis, POCT |                                                      |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------|------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                      | 3 human single donor plasma or serum samples, 0.5 mL |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                 | MonAb                                                |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                    | For clinical laboratories and POCT sites.            |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                       | JAN                                                  | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                | SFS-EN ISO/IEC 17043:2023, FINAS, PT02               |     |     |     |     | Results/set |     | 3   |     |     |     |     |

HBsAg and HCVAb, POCT

Target: POCT

| 5687 HBsAg and HCVAb, POCT |                                                                                    |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------|------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                    | 3 human plasma or serum samples, 0.5 mL                                            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations               | HBsAg and HCVAb POCT                                                               |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                  | This scheme is only for POCT users. Scheme 5094-5096 is for clinical laboratories. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                     | JAN                                                                                | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation              | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                             |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## HCV RNA from capillary blood, POCT

Target: POCT

| 5689 HCV RNA from capillary blood, POCT |                                                                                                               |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                 | 2 lyophilised or simulated liquid samples                                                                     |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                            | HCV NAT (RNA)                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                               | The product is only for units using point-of-care testing methods. Please see product 5678 for other methods. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                  | JAN                                                                                                           | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                           | Not accredited                                                                                                |     |     |     |     | Results/set |     | 1   |     |     |     |     |

## Hepatitis A, antibodies

Target: Laboratories and POCT

| 5092 Hepatitis A, antibodies |                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------|-----------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                      | 3 human single donor plasma or serum samples, 0.6 mL            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                 | HAVAb, HAVAbG, HAVAbM, post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                       | JAN                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Hepatitis B and C, serology

Target: Laboratories

| 5094 Hepatitis B and C, serology, specimen volume 0.6 mL |                                                                                                                            |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                                  | 3 human single donor plasma or serum samples, 0.6 / 1.2 / 2 mL. Choose the sample volume according to your test selection. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                             | HBsAg, HBsAgCt, HBcAb, HBcAbM, HBeAg, HBeAb, HBsAb (qual), HCVAb, HCVAbCt, post-analytical clinical interpretation.        |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                                | For clinical laboratories. Scheme 5687 is for POCT users.                                                                  |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                                   | JAN                                                                                                                        | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                            | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                     |     |     |     |     | Results/set |     | 3   |     |     |     |     |

### 5095 Hepatitis B and C, serology, specimen volume 1.2 mL

|               |                                                                                                                            |             |   |
|---------------|----------------------------------------------------------------------------------------------------------------------------|-------------|---|
| Samples       | 3 human single donor plasma or serum samples, 0.6 / 1.2 / 2 mL. Choose the sample volume according to your test selection. |             |   |
| Examinations  | HBsAg, HBsAgCt, HBcAb, HBcAbM, HBeAg, HBeAb, HBsAb (qual), HCVAb, HCVAbCt, post-analytical clinical interpretation.        |             |   |
| Add. info     | For clinical laboratories. Scheme 5687 is for POCT users.                                                                  |             |   |
| Rounds        | <div>JANFEBMARAPRMAYJUNJULAUGSEPOCTNOVDEC</div>                                                                            |             |   |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                     | Results/set | 3 |

### 5096 Hepatitis B and C serology, specimen volume 2.0 mL

|               |                                                                                                                            |             |   |
|---------------|----------------------------------------------------------------------------------------------------------------------------|-------------|---|
| Samples       | 3 human single donor plasma or serum samples, 0.6 / 1.2 / 2 mL. Choose the sample volume according to your test selection. |             |   |
| Examinations  | HBsAg, HBsAgCt, HBcAb, HBcAbM, HBeAg, HBeAb, HBsAb (qual), HCVAb, HCVAbCt, post-analytical clinical interpretation.        |             |   |
| Add. info     | For clinical laboratories. Scheme 5687 is for POCT users.                                                                  |             |   |
| Rounds        | <div>JANFEBMARAPRMAYJUNJULAUGSEPOCTNOVDEC</div>                                                                            |             |   |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                     | Results/set | 3 |

## Hepatitis B virus, nucleic acid detection (DNA)

Target: Laboratories

### 5679 Hepatitis B virus, nucleic acid detection (DNA)

|               |                                                                 |             |   |
|---------------|-----------------------------------------------------------------|-------------|---|
| Samples       | 3 lyophilised or liquid plasma samples, 1.5 mL                  |             |   |
| Examinations  | HBV DNA, quantitative and/or qualitative nucleic acid detection |             |   |
| Rounds        | <div>JANFEBMARAPRMAYJUNJULAUGSEPSEPOCTNOVDEC</div>              |             |   |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                          | Results/set | 3 |

## Hepatitis B, s-antigen antibodies

Target: Laboratories

### 5093 Hepatitis B, s-antigen antibodies, quantitative

|               |                                                      |             |   |
|---------------|------------------------------------------------------|-------------|---|
| Samples       | 2 human single donor plasma or serum samples, 0.5 mL |             |   |
| Examinations  | HBsAb (anti-HBs), quantitative                       |             |   |
| Rounds        | <div>JANFEBMARAPRMAYJUNJULAUGSEPSEPOCTNOVDEC</div>   |             |   |
| Accreditation | SFS-EN ISO/IEC 17043:2023, FINAS, PT02               | Results/set | 3 |

## Hepatitis C virus, nucleic acid detection (RNA)

**Target:** Laboratories

| 5678 Hepatitis C virus, nucleic acid detection (RNA) |                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------------------------------|-----------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                              | 3 lyophilised or liquid plasma samples, 1.5 mL                  |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                         | HCV RNA, quantitative and/or qualitative nucleic acid detection |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                               | JAN                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                        | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Hepatitis E, antibodies

**Target:** Laboratories and POCT

| 5682 Hepatitis E, antibodies |                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------|-----------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                      | 3 human single donor plasma or serum samples, 0.5 mL            |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                 | HEVAb, HEVAbG, HEVAbM, post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                       | JAN                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Herpes simplex 1 and 2, antibodies

**Target:** Laboratories

| 5555 Herpes simplex 1 and 2, antibodies |                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------|---------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                 | 3 human single donor plasma or serum samples, 0.5 mL. Occasionally simulated samples. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                            | HSV IgG (qualitative/quantitative), HSV IgM, HSV-1 IgG, HSV-2 IgG                     |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                  | JAN                                                                                   | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                           | Not accredited                                                                        |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## HIV, nucleic acid detection (RNA)

**Target:** Laboratories

| 5680 HIV, nucleic acid detection (RNA) |                                                                 |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------|-----------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                | 3 lyophilised or liquid plasma samples, 1.5 mL                  |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                           | HIV RNA, quantitative and/or qualitative nucleic acid detection |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                 | JAN                                                             | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                          | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## HIV, antibodies and antigen detection

Target: Laboratories

| 5088 HIV, antibodies and antigen detection, extra set of samples |                                                         |     |     |     |     |     |     |     |     |     |     |     |
|------------------------------------------------------------------|---------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Samples                                                          | 3 liquid or lyophilized plasma or serum samples, 0.7 mL |     |     |     |     |     |     |     |     |     |     |     |
| Add. info                                                        | Only in connection with scheme 5091.                    |     |     |     |     |     |     |     |     |     |     |     |
| Rounds                                                           | JAN                                                     | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |

| 5091 HIV, antibodies and antigen detection |                                                                                                              |     |     |     |     |             |     |     |     |     |     |     |  |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|--|
| Samples                                    | 3 liquid or lyophilized plasma or serum samples, 0.7 mL                                                      |     |     |     |     |             |     |     |     |     |     |     |  |
| Examinations                               | HIVAb (1/2), HIVAgAb (combo), HIVAg (p24), HIVAb confirmatory test, post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |  |
| Add. info                                  | The round may contain HIV-1 or HIV-2 positive samples.                                                       |     |     |     |     |             |     |     |     |     |     |     |  |
| Rounds                                     | JAN                                                                                                          | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |  |
| Accreditation                              | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                       |     |     |     |     | Results/set | 3   |     |     |     |     |     |  |

## HIV, antibodies and antigen detection, POCT

Target: POCT

| 5090 HIV, antibodies and antigen detection, POCT |                                                                                                                                                                                     |             |   |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---|
| Samples                                          | 3 human plasma or serum samples, 0.5 mL                                                                                                                                             |             |   |
| Examinations                                     | HIVAb, HIVAg (p24) POCT                                                                                                                                                             |             |   |
| Add. info                                        | This scheme is only for POCT users. Scheme 5091 is for clinical laboratories.                                                                                                       |             |   |
| Rounds                                           | <div>JAN</div> <div>FEB</div> <div>MAR</div> <div>APR</div> <div>MAY</div> <div>JUN</div> <div>JUL</div> <div>AUG</div> <div>SEP</div> <div>OCT</div> <div>NOV</div> <div>DEC</div> |             |   |
| Accreditation                                    | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                              | Results/set | 3 |

## HSV1&2/VZV/Treponema pallidum, nucleic acid detection

Target: Laboratories

| 5556 HSV1&2/VZV/Treponema pallidum, nucleic acid detection |                                                                                                                                                                                     |             |   |
|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---|
| Samples                                                    | 3 samples simulating swab samples taken from lesions.                                                                                                                               |             |   |
| Examinations                                               | Nucleic acid detection of HSV1, HSV2, VZV, Treponema pallidum.                                                                                                                      |             |   |
| Add. info                                                  | The samples contain hDNA.                                                                                                                                                           |             |   |
| Rounds                                                     | <div>JAN</div> <div>FEB</div> <div>MAR</div> <div>APR</div> <div>MAY</div> <div>JUN</div> <div>JUL</div> <div>AUG</div> <div>SEP</div> <div>OCT</div> <div>NOV</div> <div>DEC</div> |             |   |
| Accreditation                                              | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                                                                              | Results/set | 3 |

## HTLV, antibodies

**Target:** Laboratories and POCT

| 5089 Human T-cell lymphotropic virus, antibodies |                                                                                   |     |     |     |     |                    |     |     |     |     |     |     |
|--------------------------------------------------|-----------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                   | 3 human single donor plasma or serum samples, 0.5 mL                              |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                              | HTLVAb screening and confirmatory tests, post-analytical clinical interpretation. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                 | The round may contain HTLV-1 or HTLV-2 positive samples.                          |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                    | JAN                                                                               | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                             | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                            |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Human papillomavirus, nucleic acid detection

**Target:** Laboratories

| 5086 Human papillomavirus, nucleic acid detection |                                                                                                                       |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                    | 2 simulated samples, 1 mL                                                                                             |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                               | High-risk human papillomavirus NAT (hrHPVNAT).<br>HPV genotypes included are: 16, 18, 31, 33, 39, 45, 51, 52, 66, 67. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                  | Suitable for nucleic acid methods used in cervical cancer screening. The samples contain hDNA.                        |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                     | JAN                                                                                                                   | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                              | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                                |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Influenza virus A+B and RS virus, nucleic acid detection

**Target:** Laboratories and POCT

| 5670 Influenza virus A+B and RS virus, nucleic acid detection |                                                                                                                                                                     |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                                | 3 simulated samples, 1 mL                                                                                                                                           |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                           | InfANAT, InfBNAT, RSVNAT                                                                                                                                            |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                              | See also scheme 5300 Respiratory infections multiplex, nucleic acid detection or 5562 Multiple respiratory virus, nucleic acid detection. The samples contain hDNA. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                                 | JAN                                                                                                                                                                 | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                          | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. The qualitative analysis phase is accredited.                                                                               |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

Influenza virus A+B, antigen detection

Target: Laboratories and POCT

| 5671 Influenza virus A+B, antigen detection |                                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
|---------------------------------------------|-------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                     | 3 simulated samples                                                                                   |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                | InfAAg, InfBAG                                                                                        |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                   | For clinical laboratories and POCT sites. The product is intended for antigen detection methods only. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                      | JAN                                                                                                   | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                               | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                |     |     |     |     | Results/set |     | 3   |     |     |     |     |

Measles virus, antibodies

Target: Laboratories

| 5668 Measles virus, antibodies |                                                                                   |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------|-----------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                        | 3 human single donor plasma or serum samples, 0.5 mL                              |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                   | Measles virus IgG and IgM antibodies and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                         | JAN                                                                               | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                  | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                            |     |     |     |     | Results/set |     | 3   |     |     |     |     |

Mpox, nucleic acid detection

Target: Laboratories

| 5683 Mpox, nucleic acid detection |                                                         |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------|---------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                           | 2 swab samples simulating patient samples from lesions. |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                      | Mpox NAT.                                               |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                         | The samples contain hDNA.                               |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                            | JAN                                                     | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                     | Not accredited                                          |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Multiple respiratory virus, antigen detection

**Target:** Laboratories and POCT

| 5559 Multiple respiratory virus, antigen detection |                                                                                               |     |     |     |     |                    |     |     |     |     |     |     |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                     | 3 simulated swab samples                                                                      |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                | Influenza A, Influenza B, RSV, SARS-CoV-2 and Adenovirus Ag                                   |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                   | This scheme is only for antigen detection methods. Scheme 5562 is for nucleic acid detection. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                      | JAN                                                                                           | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                               | Not accredited                                                                                |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Multiple respiratory virus, nucleic acid detection

**Target:** Laboratories and POCT

| 5562 Multiple respiratory virus, nucleic acid detection |                                                                                                          |     |     |     |     |                    |     |     |     |     |     |     |
|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>                                          | 3 simulated swab samples                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>                                     | Influenza A NAT, Influenza B NAT, RSV NAT and SARS-CoV-2 NAT                                             |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Add. info</b>                                        | Scheme is not suitable for TMA methods (e.g. Hologic Aptima SARS-CoV-2 Assay). The samples contain hDNA. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                                           | JAN                                                                                                      | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>                                    | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. The qualitative analysis phase is accredited.                    |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Mumps virus, antibodies

**Target:** Laboratories

| 5669 Mumps virus, antibodies |                                                                                 |     |     |     |     |                    |     |     |     |     |     |     |
|------------------------------|---------------------------------------------------------------------------------|-----|-----|-----|-----|--------------------|-----|-----|-----|-----|-----|-----|
| <b>Samples</b>               | 3 human single donor plasma or serum samples, 0.5 mL                            |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Examinations</b>          | Mumps virus IgG and IgM antibodies and post-analytical clinical interpretation. |     |     |     |     |                    |     |     |     |     |     |     |
| <b>Rounds</b>                | JAN                                                                             | FEB | MAR | APR | MAY | JUN                | JUL | AUG | SEP | OCT | NOV | DEC |
| <b>Accreditation</b>         | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                          |     |     |     |     | <b>Results/set</b> |     | 3   |     |     |     |     |

## Norovirus, antigen detection

**Target:** Laboratories and POCT

| 5686 Norovirus, antigen detection |                                                    |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------|----------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                           | 3 simulated swab samples                           |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                      | Norovirus antigen detection, genogroups GI and GII |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                            | JAN                                                | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                     | SFS-EN ISO/IEC 17043:2023, FINAS, PT02             |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Norovirus, nucleic acid detection

**Target:** Laboratories

| 5675 Norovirus, nucleic acid detection |                                        |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------------|----------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                | 3 simulated samples, 1 mL              |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                           | Norovirus NAT, genogroups GI and GII.  |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                 | JAN                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                          | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Parvovirus (B19), antibodies

**Target:** Laboratories

| 5660 Parvovirus (B19), antibodies |                                                                               |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------|-------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                           | 3 human single donor plasma or serum samples, 0.4 mL                          |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                      | Parvovirus IgG, IgM, IgG avidity and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                            | JAN                                                                           | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                     | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                        |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Puumala virus, antibodies

**Target:** Laboratories and POCT

| 5560 Puumala virus, antibodies |                                                                                                                     |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                        | 3 plasma or serum samples, 0.3 mL. Brief case histories are also provided.                                          |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                   | Puumala virus IgG, IgM, POC tests and specific antibodies, IgG avidity and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                      | For clinical laboratories and POCT sites.                                                                           |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                         | JAN                                                                                                                 | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                  | Not accredited                                                                                                      |     |     |     |     | Results/set | 3   |     |     |     |     |     |

## Respiratory adenovirus, antigen detection

**Target:** Laboratories and POCT

| 5673 Respiratory adenovirus, antigen detection |                                        |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------------------------|----------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                        | 3 simulated samples, 1 mL              |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                   | Adenovirus Ag                          |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                         | JAN                                    | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                  | SFS-EN ISO/IEC 17043:2023, FINAS, PT02 |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Rotavirus and adenovirus, antigen detection

**Target:** Laboratories

| 5098 Rotavirus and adenovirus, antigen detection |                                             |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------------------------|---------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                          | 3 simulated samples, 1 mL                   |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                     | Rotavirus and adenovirus antigen detection. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                           | JAN                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                    | SFS-EN ISO/IEC 17043:2023, FINAS, PT02      |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## RS virus, antigen detection

**Target:** Laboratories and POCT

| 5672 RS virus, antigen detection |                                                                                                       |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------|-------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                          | 3 simulated samples                                                                                   |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                     | RSVAg                                                                                                 |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                        | For clinical laboratories and POCT sites. The product is intended for antigen detection methods only. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                           | JAN                                                                                                   | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                    | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                                |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Rubella virus, antibodies

**Target:** Laboratories

| 5667 Rubella virus, antibodies |                                                                                                |     |     |     |     |             |     |     |     |     |     |     |
|--------------------------------|------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                        | 3 human single donor plasma or serum samples, 0.5 mL                                           |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                   | Rubella virus IgG and IgM antibodies, IgG avidity and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                         | JAN                                                                                            | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                  | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                         |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## SARS-CoV-2, antigen detection

**Target:** Laboratories and POCT

| 5681 SARS-CoV-2, antigen detection |                                                    |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------------|----------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                            | 3 simulated samples                                |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                       | SARS-CoV-2 Ag                                      |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                          | This scheme is only for antigen detection methods. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                             | JAN                                                | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                      | SFS-EN ISO/IEC 17043:2023, FINAS, PT02             |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## SARS-CoV-2, nucleic acid detection

**Target:** Laboratories and POCT

| 5676 SARS-CoV-2, nucleic acid detection |                                                                                                                              |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                 | 3 simulated samples                                                                                                          |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                            | SARS-CoV-2 NAT                                                                                                               |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                               | Including variants. Scheme is not suitable for TMA methods (e.g. Hologic Aptima SARS-CoV-2 Assay). The samples contain hDNA. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                  | JAN                                                                                                                          | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                           | SFS-EN ISO/IEC 17043:2023, FINAS, PT02. The qualitative analysis phase is accredited.                                        |     |     |     |     | Results/set |     | 3   |     |     |     |     |

## Tick-borne encephalitis virus, antibodies

**Target:** Laboratories and POCT

| 5099 Tick-borne encephalitis virus, antibodies |                                                                             |     |     |     |     |             |     |     |     |     |     |     |
|------------------------------------------------|-----------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                        | 3 human single donor plasma or serum samples, 0.5 mL                        |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                                   | TBE IgG, IgM, total antibodies and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Add. info                                      | For clinical laboratories and POCT sites.                                   |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                         | JAN                                                                         | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                                  | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                      |     |     |     |     | Results/set |     | 3   |     |     |     |     |

Varicella-zoster virus, antibodies

Target: Laboratories

| 5665 Varicella-zoster virus, antibodies |                                                                                          |     |     |     |     |             |     |     |     |     |     |     |
|-----------------------------------------|------------------------------------------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                                 | 3 human single donor plasma or serum samples, 0.5 mL                                     |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                            | Varicella zoster IgG, IgM, total antibodies and post-analytical clinical interpretation. |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                                  | JAN                                                                                      | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                           | SFS-EN ISO/IEC 17043:2023, FINAS, PT02                                                   |     |     |     |     | Results/set |     | 3   |     |     |     |     |

West Nile virus, antibodies

Target: Laboratories

| 5688 West Nile virus, antibodies |                                                      |     |     |     |     |             |     |     |     |     |     |     |
|----------------------------------|------------------------------------------------------|-----|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|
| Samples                          | 3 human single donor plasma or serum samples, 0.5 mL |     |     |     |     |             |     |     |     |     |     |     |
| Examinations                     | West Nile Virus IgG, IgM and total antibodies        |     |     |     |     |             |     |     |     |     |     |     |
| Rounds                           | JAN                                                  | FEB | MAR | APR | MAY | JUN         | JUL | AUG | SEP | OCT | NOV | DEC |
| Accreditation                    | Not accredited                                       |     |     |     |     | Results/set |     | 3   |     |     |     |     |